SEC 13F Intelligence

Managers / Q3 2019 · view latest →

Ghost Tree Capital, LLC

CIK 0001595851 · 667 MADISON AVENUE, 5TH FLOOR, SUITE 12, NEW YORK, NY, 10065 · 6467790120

Reported Value
$394M
Q3 2019
Positions
44
Filings on Record
32
2019–present window
Filed
Nov 14, 2019
original filing

Summary

Ghost Tree Capital, LLC reported $394M in U.S.-listed holdings across 44 positions for Q3 2019.

Its largest position, 2655787D, represents 6.1% of the portfolio.

Compared with Q2 2019, the fund opened 12 new positions and exited 12.

Portfolio Metrics

Turnover
+31.2%
vs prior filed quarter
Top-10 Concentration
+40.3%
share of reported value
Largest Position
+6.1%
Blueprint Medicines
New / Exited
12 / 12
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $285MQ4 ’18Q1 ’19: $369MQ2 ’19: $477MQ3 ’19: $394MQ3 ’19Q4 ’19: $529MQ1 ’20: $377MQ2 ’20: $379MQ2 ’20Q3 ’20: $346MQ4 ’20: $449MQ1 ’21: $425MQ1 ’21Q2 ’21: $364MQ3 ’21: $342MQ4 ’21: $279MQ4 ’21Q1 ’22: $461MQ2 ’22: $192MQ3 ’22: $356MQ3 ’22Q4 ’22: $234MQ1 ’23: $338MQ2 ’23: $303MQ2 ’23Q3 ’23: $304MQ4 ’23: $306MQ1 ’24: $361MQ1 ’24Q2 ’24: $319MQ3 ’24: $331Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 64.9%ETP: 23.5%Other: 9.4%ADR: 2.2%
  • Common Stock · 64.9% · $256M
  • ETP · 23.5% · $93M
  • Other · 9.4% · $37M
  • ADR · 2.2% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR S&P 500 ETF TRNEW+100.0K100.0K+$30M$30M
FXBINVESCO CURNCYSHS BRIT PND SNEW+105.6K105.6K+$13M$13M
BMRNBIOMARIN PHARMACEUTICAL INCNEW+185.0K185.0K+$12M$12M
PCRXPACIRA BIOSCIENCESNEW+250.0K250.0K+$10M$10M
ADVMCHFADVERUM BIOTECHNOLOGIES INCNEW+1.45M1.45M+$8M$8M
ATNXEURATHENEX INCNEW+522.5K522.5K+$6M$6M
FATEFATE THERAPEUTICS INCNEW+350.0K350.0K+$5M$5M
TURNING POINT THERAPEUTICS INEW+125.0K125.0K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

39 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
12655787DBLUEPRINT MEDICINES CORPhistory →COM6.07%$24M325.0K
2MRTXEURMIRATI THERAPEUTICS INChistory →COM5.44%$21M275.0K
3SRPTSAREPTA THERAPEUTICS INChistory →COM4.21%$17M220.0K
4SG7SAGE THERAPEUTICS INChistory →COM3.92%$15M110.0K
5BIOHAVEN PHARMACTL HLDG CO LCOM3.71%$15M350.0K
6ASCENDIS PHARMA A SSPONSORED ADR3.67%$14M150.0K
7AM6AMICUS THERAPEUTICS INChistory →COM3.47%$14M1.71M
8AXSMAXSOME THERAPEUTICS INChistory →COM3.47%$14M675.0K
9FXBINVESCO CURNCYSHS BRIT PND Shistory →BRIT POUN STRL3.20%$13M105.6K
10BMRNBIOMARIN PHARMACEUTICAL INChistory →COM3.17%$12M185.0K
11IMMUIMMUNOMEDICS INChistory →COM2.44%$10M725.0K
12PCRXPACIRA BIOSCIENCEShistory →COM2.42%$10M250.0K
13IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM2.31%$9M500.0K
14ADVMCHFADVERUM BIOTECHNOLOGIES INChistory →COM2.01%$8M1.45M
15RCKTROCKET PHARMACEUTICALS INChistory →COM1.85%$7M625.0K
16ATNXEURATHENEX INChistory →COM1.61%$6M522.5K
17ARGXARGENX SEhistory →SPONSORED ADR1.45%$6M50.0K
18FATEFATE THERAPEUTICS INChistory →COM1.38%$5M350.0K
19TURNING POINT THERAPEUTICS ICOM1.19%$5M125.0K
20MNTAMOMENTA PHARMACEUTICALS INChistory →COM1.15%$5M350.0K
21KDMNKADMON HLDGS INChistory →COM1.12%$4M1.75M
22FXFINVESCO CURNCYSHS SWISS FRANhistory →SWISS FRANC1.12%$4M47.5K
23MISTMILESTONE PHARMACEUTICALS INhistory →COM1.11%$4M235.0K
24AERIEURAERIE PHARMACEUTICALS INChistory →COM1.10%$4M225.0K
25BCRXBIOCRYST PHARMACEUTICALShistory →COM1.09%$4M1.50M
26HOMOLOGY MEDICINES INCCOM1.03%$4M225.0K
27RETAEURREATA PHARMACEUTICALS INChistory →CL A1.02%$4M50.0K
28ARVNARVINAS INChistory →COM1.01%$4M185.0K
294XC1KALVISTA PHARMACEUTICALS INCCOM0.93%$4M315.0K
30DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.86%$3M235.0K
31PTGXPROTAGONIST THERAPEUTICS INCCOM0.76%$3M250.0K
32ORTXUSDORCHARD THERAPEUTICS PLCADS0.73%$3M242.9K
33VRAYQVIEWRAY INCCOM0.61%$2M825.0K
34CYMABAY THERAPEUTICS INCCOM0.57%$2M440.0K
35AVROBIO INCCOM0.56%$2M155.3K
36CHMACHIASMA INCCOM0.48%$2M382.5K
37EPZMEUREPIZYME INCCOM0.35%$1M132.0K
38SOLID BIOSCIENCES INCCOM0.26%$1M100.0K
39DERMEURDERMIRA INCCOM0.07%$272,00042.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$331M54Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$319M63Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$361M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$306M52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$304M70Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$303M57Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$338M58May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$234M35Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$356M44Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$192M34Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$461M42May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$279M47Feb 16, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M60Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M52Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$425M50May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$449M43Feb 18, 2021RESTATEMENTchanges · EDGAR ↗
Q3 2020$346M47Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$379M43Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$377M49May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$529M53Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$394M44Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$477M43Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$369M39May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$285M39Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.